Artificial intelligence (AI) is quickly becoming a competitive differentiator for biopharma companies. While there's no clear victor yet, there are a few businesses that have built AI into the center of their strategy.

To get an idea about how big of an impact AI is having already, let's take a look at what two of these innovators are doing with AI, and why it matters to investors.

Ginkgo Bioworks (NYSE: DNA) is using AI to help other biopharma businesses produce more of the biomolecules and bioengineered organisms they need -- and more cheaply than they can do it on their own.

Continue reading

Source Fool.com